GR3030867T3 - Guanidine derivatives useful in therapy - Google Patents

Guanidine derivatives useful in therapy

Info

Publication number
GR3030867T3
GR3030867T3 GR990401953T GR990401953T GR3030867T3 GR 3030867 T3 GR3030867 T3 GR 3030867T3 GR 990401953 T GR990401953 T GR 990401953T GR 990401953 T GR990401953 T GR 990401953T GR 3030867 T3 GR3030867 T3 GR 3030867T3
Authority
GR
Greece
Prior art keywords
therapy
derivatives useful
guanidine derivatives
condition
disease
Prior art date
Application number
GR990401953T
Other languages
Greek (el)
Inventor
James Edwin Macdonald
Robert James Gentile
Robert John Murray
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939305997A external-priority patent/GB9305997D0/en
Priority claimed from GB939306767A external-priority patent/GB9306767D0/en
Priority claimed from GB939307741A external-priority patent/GB9307741D0/en
Application filed by Astra Ab filed Critical Astra Ab
Publication of GR3030867T3 publication Critical patent/GR3030867T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Method of treating or reducing the risk of human disease or condition in which the synthesis or oversynthesis of nitric oxide forms a contributory part wherein a therapeutically effective amount of the compound of formula (I) as defined in the specification is administered to a person suffering from or susceptible to such disease or condition.
GR990401953T 1993-03-23 1999-07-27 Guanidine derivatives useful in therapy GR3030867T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB939305997A GB9305997D0 (en) 1993-03-23 1993-03-23 Pharmaceutically active compounds
GB939306767A GB9306767D0 (en) 1993-03-31 1993-03-31 Pharmaceutically active compounds
GB939307741A GB9307741D0 (en) 1993-04-15 1993-04-15 Pharmaceutically active compounds
PCT/GB1994/000584 WO1994021621A1 (en) 1993-03-23 1994-03-22 Guanidine derivatives useful in therapy

Publications (1)

Publication Number Publication Date
GR3030867T3 true GR3030867T3 (en) 1999-11-30

Family

ID=27266630

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990401953T GR3030867T3 (en) 1993-03-23 1999-07-27 Guanidine derivatives useful in therapy

Country Status (9)

Country Link
US (2) US5885985A (en)
EP (1) EP0690851B1 (en)
AT (1) ATE180255T1 (en)
AU (1) AU6286294A (en)
DE (1) DE69418601T2 (en)
DK (1) DK0690851T3 (en)
ES (1) ES2132393T3 (en)
GR (1) GR3030867T3 (en)
WO (1) WO1994021621A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE231126T1 (en) * 1993-08-12 2003-02-15 Astrazeneca Ab AMIDINE DERIVATIVES WITH NITROGEN OXIDE SYNTHEASE ACTIVITY
MX9605366A (en) * 1994-05-07 1997-12-31 Astra Ab Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase.
US5665757A (en) * 1994-07-13 1997-09-09 Robert W. Dunn Method for treating anxiety
GB9418912D0 (en) * 1994-09-20 1994-11-09 Fisons Corp Pharmaceutically active compounds
WO1996018607A1 (en) * 1994-12-12 1996-06-20 Chugai Seiyaku Kabushiki Kaisha Aniline derivative having the effect of inhibiting nitrogen monoxide synthase
WO1996021445A1 (en) * 1995-01-13 1996-07-18 The General Hospital Corporation Methods of inhibiting neurodegenerative diseases
CZ287969B6 (en) * 1995-08-10 2001-03-14 Astra Pharmaceuticals Limited Amidine derivative, process of its preparation and pharmaceutical preparation in which containing thereof and its use
US6140322A (en) * 1995-11-07 2000-10-31 Astra Aktiebolag Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
TW458978B (en) * 1995-11-07 2001-10-11 Astra Ab Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
US5908842A (en) * 1995-12-08 1999-06-01 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
US6756389B2 (en) * 1996-08-09 2004-06-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
US5929085A (en) * 1996-11-06 1999-07-27 Astra Aktiebolag Amidine and isothiourea derivatives, compositions containing them and their use as inhibitors of nitric oxide synthase
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
FR2761066B1 (en) * 1997-03-24 2000-11-24 Sod Conseils Rech Applic NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6335445B1 (en) 1997-03-24 2002-01-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
FR2784678B1 (en) * 1998-09-23 2002-11-29 Sod Conseils Rech Applic NOVEL N- (IMINOMETHYL) AMINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2783519B1 (en) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic NOVEL AMIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SE9904677D0 (en) * 1999-12-20 1999-12-20 Astra Ab Novel compounds
SE9904676D0 (en) * 1999-12-20 1999-12-20 Astra Ab Novel compounds
US20040087798A1 (en) * 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
DZ3415A1 (en) 2000-08-31 2002-03-07 Chiron Corp GUANIDINOBENZAMIDES AS MC4-R AGONISTS.
EP1767525A1 (en) 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
WO2003027068A2 (en) * 2001-09-24 2003-04-03 Elan Pharmaceuticals, Inc. Substituted amines for the treatment of neurological disorders
DE10162114A1 (en) * 2001-12-12 2003-06-26 Schering Ag New N-phenyl (hetero)aryl-carboximidamides are potent nitrogen monoxide synthase inhibitors, useful e.g. for treating neurodegenerative, cardiovascular, autoimmune and/or inflammatory diseases
US20030207814A1 (en) * 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US20050124652A1 (en) * 2002-02-04 2005-06-09 Rustum Boyce Guanidino compounds
WO2003072056A2 (en) * 2002-02-25 2003-09-04 Chiron Corporation Intranasal administration of mc4-r agonists
MXPA04011557A (en) * 2002-05-23 2005-07-05 Chiron Corp Substituted quinazolinone compounds.
JP2007501861A (en) * 2003-05-23 2007-02-01 カイロン コーポレイション Guanidino-substituted quinazolinone compounds as MC4-R agonists
MXPA06005736A (en) 2003-11-19 2006-12-14 Chiron Corp Quinazolinone compounds with reduced bioaccumulation.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1341245A (en) * 1971-07-08 1973-12-19 Vnii Chim Sredstv Zaschity Substituted guanidines and fungicidal compositions comprising substituted guanidines
US3976643A (en) * 1973-07-13 1976-08-24 William H. Rorer, Inc. Guanidines
US4211867A (en) * 1976-03-19 1980-07-08 Mcneil Laboratories, Incorporated Nitrogen heterocyclic carboximidamide compounds
NZ183570A (en) * 1976-03-19 1979-06-08 Mcneilab Inc Heterocyclic guanidine derivatives, having anti-secretory and hypogliycaemic activity
US4182865A (en) * 1978-09-18 1980-01-08 Mcneil Laboratories, Inc. Diaza-cyclic derivatives of guanidine
US4414211A (en) * 1978-09-18 1983-11-08 Mcneilab, Inc. Heterocyclic derivatives of guanidine
US4345083A (en) * 1978-09-18 1982-08-17 Mcneilab, Inc. (1-Methyl-2-quinolinylidene) derivatives of guanidine
CA1201119A (en) * 1978-09-18 1986-02-25 Mcneilab, Inc. Diaza-cyclic derivatives of guanidine
JPS55160764A (en) * 1979-05-29 1980-12-13 Ciba Geigy Ag Guanidine* its manufacture and pharmaceutic medicine containing same
GR71929B (en) * 1979-11-13 1983-08-19 Ici Ltd
IE62023B1 (en) * 1989-01-02 1994-12-14 Boots Co Plc Therapeutic agents
EP0517852B1 (en) * 1990-03-02 2002-07-10 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
IN172842B (en) * 1990-05-17 1993-12-11 Boots Pharmaceuticals Limited
US5268373A (en) * 1992-07-28 1993-12-07 Mcneilab, Inc. Guanidine derivatives, compositions and use
WO1995014465A2 (en) * 1993-11-22 1995-06-01 The Johns Hopkins University Methods for amelioration of immunodeficiency virus induced neurodegeneration by covering nitric oxide or superoxide concentration

Also Published As

Publication number Publication date
DE69418601T2 (en) 1999-09-30
DE69418601D1 (en) 1999-06-24
US5885985A (en) 1999-03-23
DK0690851T3 (en) 1999-11-08
AU6286294A (en) 1994-10-11
WO1994021621A1 (en) 1994-09-29
US5998399A (en) 1999-12-07
ES2132393T3 (en) 1999-08-16
EP0690851A1 (en) 1996-01-10
EP0690851B1 (en) 1999-05-19
ATE180255T1 (en) 1999-06-15

Similar Documents

Publication Publication Date Title
GR3030867T3 (en) Guanidine derivatives useful in therapy
BE2018C038I2 (en)
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
KR950700749A (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M phase specific antineoplastic agent)
PL310474A1 (en) Application of rilusole in treating neuro-aids diseases
DE68912195D1 (en) Use of pyrrolicloncarboxylic acid alkyl esters for the manufacture of a medicament for the treatment of ichthyosis.
GB2285219B (en) Use of norastemizole for the treatment of allergic disorders
ZA898605B (en) Compositions for topical treatment of skin diseases
DE69521536T2 (en) Compositions containing G-CSF and a TNF binding protein
WO2002039999B1 (en) Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
MY118244A (en) Alfa-amino acid amides, preparation thereof and the therapeutical use thereof
ZA962635B (en) Composition and process for prevention and treatment of cutaneous immediate hypersensitivity reactions
AU1494395A (en) The use of deoxyspergualin for preparing a pharmaceutical for treating hyperreactive inflammatory diseases
EP0642338A1 (en) USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE.
NZ268039A (en) Use of efaroxan in treating parkinson's disease
GR3015132T3 (en) Novel ureas and thioureas, preparation thereof and application in therapy.
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
RU94044455A (en) Agent for macrophage function enhancement and human treatment with attenuated immunity
MX9701528A (en) 1,1,2-triphenylbut-1-ene derivatives for treating alzheimers disease.